LondonA model now generates molecules for chosen targets.
Neglected-disease drug programs get more compounds worth testing.
Flow matching learns a path from noise to a molecule, steered toward a chosen property.
The paper’s designs are computational hits, not validated compounds yet.
Sources: Nature